Research Article
Validation and Refinement of the Baveno VI Criteria for Ruling Out High-Risk Varices
Table 2
Refinement of the Baveno VI criteria.
| | Author | Patients | Criteria | Prevalence of HRV (, %) | Spared endoscopy (%) | Missed HRVs/saved endoscopies | Missed HRVs/total HRVs |
| | Ding [54] | 271, mixed | | 26 (10%) | 107/271 (39%) | 0/107 (0%) | 0/26 (0%) | | Puigvehi [55] | 368, HCV | | 55 (15%) | 149/368 (40.5%) | 10/149 (6.7%) | 10/55 (18.2%) | | Jangouk [66] | 262, mixed | | | | | | US cohort (161) | Baveno VI | 14 (9%) | 41/161 (25.4%) | 0/41 (0%) | 0/14 (0%) | | 14 (9%) | 60/161 (37.3%) | 0/60 (0%) | 0/14 (0%) | | 14 (9%) | 86/161 (53.4%) | 0/86 (0%) | 0/14 (0%) | | Italian cohort (101) | Baveno VI | 17 (17%) | 16/101 (15.8%) | 0/16 (0%) | 0/17 (0%) | | 17 (17%) | 28/101 (27.7%) | 0/28 (0%) | 0/17 (0%) | | 17 (17%) | 30/101 (29.7%) | 1/30 (3.3%) | 1/17 (5.8%) | | Augustin [52] | 925, mixed | | 92 (10%) | 367/925 (40%) | 6/367 (1.6%) | 6/92 (6.5%) | | 92 (10%) | 405/883 (45.8%) | 7/405 (1.7%) | 7/92 (7.6%) | | Petta [32] | 790, NAFLD | (M probe) training cohort: | | | | | | Baveno VI | 32 (10%) | 106/314 (33.8%) | 1/106 (0.9%) | 1/32 (3.1%) | | 32 (10%) | 182/314 (58%) | 7/182 (3.8%) | 7/32 (21.9%) | | 32 (10%) | 215/314 (68.5%) | 9/215 (4.2%) | 9/32 (28.1%) | | Validation cohort: | | | | | | Baveno VI | 45 (13%) | 113/338 (33.4%) | 5/113 (4.4%) | 5/45 (11.1%) | | 45 (13%) | 183/338 (54.1%) | 8/183 (4.4%) | 8/45 (17.8%) | | 45 (13%) | 209/338 (61.8%) | 10/209 (4.8%) | 10/45 (22.2%) | | (XL probe) training cohort: | | | | | | 32 (10%) | 204/314 (65%) | 10/204 (4.9%) | 10/32 (31.3%) | | Validation cohort: | | | | | | 14 (10%) | 64/138 (46.4%) | 1/64 (1.6%) | 1/14 (7.1%) | | Bae [51] | 282, mixed | Baveno VI | 55 (20%) | 78/282 (27.6%) | 3/78 (3.8%) | 3/55 (5.5%) | | 55 (20%) | 146/282 (51.7%) | 10/146 (6.8%) | 10/55 (18.2%) | | Colecchia [63] | 498, mixed | Internal cohort: | | | | | | Baveno VI | 46 (19%) | 52/240 (21.7%) | 1/52 (1.9%) | 1/46 (2.2%) | | 46 (19%) | 86/240 (35.8%) | 1/86 (1.2%) | 1/46 (2.2%) | | 46 (19%) | 105/240 (43.8%) | 2/105 (1.9%) | 2/46 (4.3%) | | External cohort: | | | | | | Baveno VI | 15 (13%) | 19/115 (16.5%) | 0/19 (0%) | 0/15 (0%) | | 15 (13%) | 35/115 (30.4%) | 0/35 (0%) | 0/15 (0%) | | 15 (13%) | 43/115 (37.4%) | 0/43 (0%) | 0/15 (0%) | | Tosetti [68] | 442, mixed | Baveno VI | 31 (7%) | 86/442 (19.5%) | 0/86 (0%) | 0/31 (0%) | | 31 (7%) | 193/442 (43.7%) | 0/193 (0%) | 0/31 (0%) | | 31 (7%) | 154/442 (34.8%) | 0/154 (0%) | 0/31 (0%) | | 31 (7%) | 171/442 (38.7%) | 3/171 (1.8%) | 3/31 (9.7%) | | Lee [53] | 1218, mixed | Baveno VI | 249 (20%) | 313/1218 (25.7%) | 6/313 (1.9%) | 6/249 (2.4%) | | 249 (20%) | 476/1218 (39.1%) | 21/476 (4.4%) | 21/249 (8.4%) | | 249 (20%) | 476/1218 (39.1%) | 23/476 (4.8%) | 23/249 (9.2%) | | 249 (20%) | 530/1218 (43.5%) | 31/530 (5.8%) | 31/249 (12.4%) | | 249 (20%) | 381/1218 (31.3%) | 16/381 (4.2%) | 16/249 (6.4%) | | 249 (20%) | 536/1218 (44.0%) | 23/536 (4.3%) | 23/249 (9.2%) | | Stefanescu [64] | 185, mixed | Baveno VI | 43 (23%) | 15/185 (8.1%) | 0/15 (0%) | 0/43 (0%) | | 43 (23%) | 49/185 (26.5%) | 2/49 (4.1%) | 2/43 (4.7%) | | 43 (23%) | 72/185 (38.9%) | 2/72 (2.8%) | 2/43 (4.7%) | | Protopapas [71] | 107, mixed | PLT/log10LSM | 22 (21%) | 22/107 (20.6%) | 0/22 (0%) | 0/22 (0%) |
|
|
Note: HCV—hepatitis C virus; HRV—high-risk varices; LSM—liver stiffness measurement; LSPS—liver stiffness-spleen diameter to platelet ratio score; MELD—model for end-stage liver disease; NAFLD—nonalcoholic fatty liver disease; PLT—platelet; SSM—spleen stiffness measurement.
|
